Daewoong Pharmaceutical Launches Botulinum Toxin 'Nabota' in Germany and Austria
Local Product Name 'Nusiba'
Second Largest in the European Union Released in Germany
Daewoong Pharmaceutical announced on the 28th that its botulinum toxin (BTX) product 'Nusiba' (domestic product name Nabota) has been officially launched in Germany and Austria through Evolus, its partner for advanced countries' aesthetic indications.
Evolus, Daewoong Pharmaceutical's partner in the North American and European Union regions, is responsible for the distribution and marketing of Nusiba in Germany and Austria. Evolus has formed a strategic partnership with Novia, a local aesthetic medical distributor, to prepare for the local launch. They have been conducting product marketing activities targeting local medical professionals since mid-month.
According to the DRG data report, the BTX market in Germany is estimated to be worth 100 billion KRW this year. It is the second largest market within the European Union, where the annual market size reaches approximately 690 billion KRW. Since Germany is the most populous country in the European Union, Daewoong Pharmaceutical explains that this launch will be a crucial foothold for expanding Nusiba's market share within the region.
Park Sung-soo, Vice President of Daewoong Pharmaceutical, stated, "Following the launch in the UK, the largest market in the region, the release in Germany and Austria further strengthens Nusiba's brand awareness and position within the European Union market." He added, "We expect Nusiba to showcase the excellent product quality of K-bio and K-toxin in the European Union, the world's second largest toxin market."
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Don't Throw Away Coffee Grounds" Transformed into 'High-Grade Fuel' in Just 90 Seconds [Reading Science]
- CJ Group Reports Police over Leak of Female Employees' Personal Information
- The Unexpected Story of an American Man Who Won the Lottery 18 Times in 29 Years: "My Real Luck Is My Wife"
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
Nabota, the BTX formulation developed and manufactured by Daewoong Pharmaceutical, is the only product in Korea and Asia to have obtained approval from the U.S. Food and Drug Administration (FDA). As of February 2023, it has received product approval in over 60 countries and signed export contracts with more than 80 countries.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.